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Essentials
• Abdominal aortic aneurysm (AAA) is asymptomatic and its evolution unpredictable.
• To find novel potential biomarkers of AAA, microvesicles are an excellent source of biomarkers.
• Ficolin-3 is increased in microvesicles obtained from activated platelets and AAA tissue.
• Increased ficolin-3 plasma levels are associated with AAA presence and progression.
Summary. Background: Abdominal aortic aneurysm (AAA) patients are usually asymptomatic and AAA evolution is unpredictable. Ficolin-3, mainly synthesized by the liver, is a molecule of the lectin complement-activation pathway involved in AAA pathophysiology. Objectives: To define extra-hepatic sources of ficolin-3 in AAA and investigate the role of ficolin-3 as a biomarker of the presence and progression of AAA. Methods: Microvesicles (exosomes and microparticles) were isolated from culture-conditioned medium of ADP-activated platelets, as well as from AAA tissue-conditioned medium (thrombus and wall). Ficolin-3 levels were analyzed by westernblot, real-time PCR, immunohistochemistry and ELISA. Results: Increased ficolin-3 levels were observed in microvesicles isolated from activated platelets. Similarly, microvesicles released from AAA tissue display increased ficolin-3 levels as compared with those from healthy tissue. Moreover, ficolin-3 mRNA levels in the AAA wall were greatly increased compared with healthy aortic walls. Immunohistochemistry of AAA tissue demonstrated increased ficolin-3, whereas little staining was present in healthy walls. Finally, increased ficolin-3 levels were observed in AAA patients' plasma (n = 478) compared with control plasma (n = 176), which persisted after adjustment for risk factors (adjusted odds ratio [OR], 5.29; 95% confidence interval [CI], 3.27, 8.57)]. Moreover, a positive association of ficolin-3 with aortic diameter (Rho, 0.25) and need for surgical repair was observed, also after adjustment for potential confounding factors (adjusted hazard ratio, 1.55; 95% CI, 1.11, 2.15). Conclusions: In addition to its hepatic expression, ficolin-3 may be released into the extracellular medium via microvesicles, by both activated cells and pathological AAA tissue. Ficolin-3 plasma levels are associated with the presence and progression of AAA, suggesting its potential role as a biomarker of AAA.
Introduction
Abdominal aortic aneurysm (AAA) is an important health problem, which occurs in up to 9% of adults over 65 years of age, causing about 1-2% of male deaths in Western countries. AAA is defined as a focal dilation of the abdominal aorta that exceeds more than 50% of the original aortic diameter and/or 3 cm [1] . AAA is characterized by formation of an intraluminal thrombus, which participates in extracellular matrix degradation by proteolysis and oxidative stress, leading to an immune inflammatory response of the aortic wall [2] . Currently, the only treatment for AAA is surgery, which is indicated when the aortic diameter exceeds 5.5 cm. There is no specific treatment for those AAA patients with aortic diameter between 3 and 5 cm, other than being kept under surveillance and treated for cardiovascular risk factors. However, AAA progression towards rupture is not linear, but usually presents as periods of acceleration, which can occur at any time [3] . Because AAAs are usually asymptomatic, the present clinical challenges are 2-fold: to achieve early diagnosis and to elucidate the biological mechanisms responsible for the progressive dilatation and final rupture of the aorta in order to develop new diagnostic and therapeutic approaches.
Microvesicles (including microparticles-MP-and exosomes) are an interesting biological source of circulating biomarkers of atherothrombosis [4] . Blood-borne microvesicles are mainly derived from activated platelets [5] , although leukocytes, red blood cells and endothelial cells can also participate in this process [4] . In this respect, platelet-derived microparticles are increased in thrombus-conditioned medium and plasma of AAA patients [6] . More recently, following a proteomic approach, we described increased ficolin-3 (a.k.a. H-ficolin or hakata antigen) levels in microvesicles isolated from the plasma of patients with AAA [7] . Ficolin-3 is expressed from the FCN3 gene and is constitutively synthesized in the liver and lung, but can be induced in a number of tissues [8] . However, during an immuneinflammatory response, extra-hepatic expression occurs, as recently observed, for instance, in the lung [9] . Ficolin-3 is the most abundant and most efficient recognition molecule in the lectin pathway of the complement system [10] . The complement system plays a major role in innate immunity, participating in host defense responses against microorganisms (via opsonization, chemoattraction of leukocytes and cell activation) and bridging innate and adaptive immunity [11] . Moreover, ficolin-3 has been shown to be involved in the removal of dying host cells and cellular debris by the exposure of hidden ligands in the host tissue [12] . Regarding the potential role of ficolin-3 as a biomarker of vascular diseases, increased levels of ficolin-3 have been previously detected in patients with chronic carotid atherosclerosis [13] . In contrast, low ficolin-3 levels were observed in the acute phase in stroke patients [13] . Although the lectin pathway of complement activation has been implicated in AAA pathogenesis [14] , no studies have addressed the potential role of ficolin-3 as a biomarker of AAA.
Based on these recent results, our hypothesis was that ficolin-3 could be a potential biomarker of AAA. This study was designed (i) to address potential extra-hepatic sources responsible for the increased extracellular ficolin-3 levels in AAA; (ii) to analyze systemic ficolin-3 concentrations in patients with AAA and controls and (iii) to analyze the potential prognostic value of systemic ficolin-3 determination in AAA patients in a 5-year follow-up. Finally, we also tested how the ficolin-3 levels compared with those of C-reactive protein (CRP), which is an established risk marker in AAA patients, previously tested in the same cohort [15] .
Material and methods

Platelet isolation
Platelet-rich plasma was isolated from whole blood of healthy volunteers by centrifugation in EDTA tubes (200 9 g, 10 min without brake). Platelets were pelleted by centrifugation for 10 min at 2500 g and resuspended in roswell park memorial institute (RPMI) 1640. Platelets (5 9 10 6 cells) were incubated with adenosine diphosphate (ADP, Sigma Aldrich, Madrid, Spain) for 2 h at a final concentration of 10 lmol L À1 .
Tissue and tissue-conditioned media
Ten AAA samples (thrombus and wall) were collected during surgical repair from patients enrolled in the REflet Sanguin de l' evolutivit e des An evrysmes de l'Aorte abdominale protocol [16] . Ten control aortas were sampled from dead organ donors with the authorization of the French Biomedicine Agency (PFS 09-007). These control aortic samples were macroscopically normal and devoid of early atheromatous lesions. The AAA thrombus and wall, as well as healthy aortic wall, were cut into small pieces (5 mm 2 ) and separately incubated in RPMI 1640 medium without fetal bovine serum (FBS) for 24 h at 37°C (6 mL g À1 of wet tissue). The tissue-conditioned medium was collected after centrifugation at 3000 g for 10 min at 20°C and frozen at À80°C.
Microvesicle isolation and characterization
Exosome-like vesicles and microparticles were isolated from platelet-and tissue-conditioned media. Briefly, cell or tissue supernatants were centrifuged at increasing speeds in order to discard cells (300 g, 10 min), dead cells and debris (2000 g, 10 min), and to obtain microparticles (20 000 g, 30 min twice). After that, two ultracentrifugations (100 000 g, 70 min) were performed to pellet the small vesicles that correspond to exosomes and to discard contaminating proteins. Microparticles and exosomes were resuspended in lysis buffer (for SDS-PAGE analysis). Moreover, microparticles were also resuspended in PBS 
Western blot
Proteins from platelet-or tissue-conditioned media were resolved in SDS-PAGE. For platelet-conditioned media, we used the same volume (0.5 mL, which was concentrated by a 10K centrifugal filter, Amicon, Millipore, Madrid, Spain) from the same number of cells for each condition (5 9 10 6 cells). For tissue-conditioned media, we normalized the procedure by incubating each gram of wet tissue in 6 mL of RPMI alone (without FBS) and then an equal amount of protein (20 ug) was subjected to SDS-PAGE. The protein concentration of microvesicles in the different conditions was similar (Table S1 ). Membranes were incubated with a mouse monoclonal antibody against ficolin-3 (clone FCN309, IgG1) [17] and processed as previously described [18] .
Immunohistochemistry AAA (thrombus and wall) and control aortic wall tissue samples were fixed in 3.7% paraformaldehyde, embedded in paraffin and sectioned at 6 lm. Sections were deparaffinized, hydrated and incubated with anti-ficolin-3 polyclonal antibody as primary antibody (made in sheep, produced and characterized in our own laboratory, in which recombinant full-length ficolin-3 was used as an immunogen) or with irrelevant immunoglobulin (used at the same concentration, Dako, Santa Clara, CA, USA) in order to assess non-specific staining. Sections were then counterstained with hematoxylin.
Real-time polymerase chain reaction
Human pathological and control tissues were snap frozen in N 2 liquid and homogenates (0.2 g) were divided and resuspended for mRNA analysis. Total RNA was obtained by the TRIzol method (Life Technologies, Waltham, MA, USA) and quantified by absorbance at 260 nm, in duplicate. The A260/A280 ratio was measured in every sample to test mRNA purity; the sample was discarded or RNA extraction repeated when it was out of the 1.8-2 range. Real-time PCR was performed as previously described [18] . The expression of ficolin-3 was normalized to housekeeping transcripts (18S). The following TaqMan probes were purchased from Applied Biosystems (Madrid, Spain) and optimized according to the manufacturer's protocol: Fcn3 (Hs 00892390_m1) and 18S (4310893E).
Patients
In an ongoing randomized population-based screening trial for AAA, peripheral arterial disease (PAD) and hypertension in more than 50 000 men aged from 65 to 74 years from the central region of Denmark (ClinicalTrials.gov NCT00662480) [19] , baseline plasma samples were taken consecutively at diagnosis from 478 AAA patients and 176 age-matched controls without AAA or PAD attending the screening trial. AAA was defined as a maximal aortic diameter greater than 30 mm and PAD was defined as an ankle-brachial index (ABI) lower than 0.90 or > 1.4. AAA cases among first-degree relatives, smoking status, coexisting diabetes mellitus, hypertension and use of b-blockers, b-agonists, angiotensin-converting enzyme (ACE) inhibitors, aspirin and statins were recorded. Body mass index (BMI) and systolic and diastolic blood pressure were also measured and recorded. Ankle systolic blood pressure was also measured, as previously validated and reported [20] , and maximal anterior-posterior diameter of the infrarenal aorta was measured at the peak of systole from the inner edge to the outer edge of the aorta [21] . The ABI was calculated as the mean of the two recorded ankle arterial blood pressures divided by the brachial systolic blood pressure.
To quantify the size of an AAA more accurately by taking the commonly observed ellipse-shaped configuration into consideration, patients with AAAs underwent a semi-automated measurement of the outer maximal area at the level of the largest AP diameter by one observer at baseline. The intra-observer variation of this outer maximal AAA area is 0.99 in a test of 2 9 25 measurements. There were no missing data at baseline. Patients with AAAs of less than 50 mm diameter were offered annual control scans by the screening team. The inter-observer variation of aortic diameter measurements was 1.52 mm. Patients with AAA diameter measuring 50 mm or more were referred for a computed tomography (CT) scan and vascular surgical evaluation. If no repair was indicated, the vascular surgical departments took over the management because of the need for closer surveillance. We have no data on loss to follow-up during such surveillance.
However, information on performed repairs and vital surveillance of the aneurysmal cases was received from the nationwide patient administrative system. One hundred and eighty-nine patients received surgery during a mean observation period of 5.16 years and a total observation time of 2611.2 days. Risk selection bias is minimal due to the population-based setting and information bias unlikely as all had an ultrasound scan and the national data source for patients who received surgery is very reliable for such data.
Blood samples were centrifuged at 3000 g for 12 min, aliquoted and stored at À80°C until analysis. Informed consent was obtained from all subjects before participation and the study was approved by the Local Ethics Committee of the Central Denmark Region, Denmark, and performed in accordance with the Helsinki Declaration.
Ficolin-3 ELISA
Plasma levels of ficolin-3 were quantified in a specific sandwich ELISA with a mouse monoclonal antibody against ficolin-3 (clone FCN334) used for both capture and detection according to a previously described method [17] .
Statistics
Probability plots and one-sample Kolmogorov-Smirnov tests were used to check for normal distribution of data. Dichotomous variables were expressed as proportions and compared between cases and controls by the chi-squared test, whereas continuous variables were tested by the Mann-Whitney U-test to identify potential confounders. Associations with a probability below 0.10 were considered to be potential confounders and used in multivariate analyses. Receiver operating characteristic (ROC) curve analysis was performed to discriminate AAA patients from control subjects, and the predictive potential was compared with the ROC curve analysis of C-reactive protein by R statistics. For the analysis of the ROC curve, the null hypothesis was that the test had a performance similar to the diagonal line (the area under the curve was 0.5). If the lowest 95% confidence limit for the area under the curve (AUC) was greater than 0.5, a significant predictive test was said to be present. The association between ficolin-3 and maximal anterior-posterior aortic diameter was studied by Spearman 0 s correlation analysis. Multivariate logistic regression analysis was performed to assess the association between ficolin-3 and the risk of AAA, adjusting for the potential identified confounders. Potential confounders were defined as having a probability of below 10% of no association with time to surgery. These potential confounders were also used in Cox regression analysis concerning an association between the need for later surgical repair and ficolin-3 or CRP concentration above and below the median. Statistics were performed using SPSS software (23.0; SPSS Inc., Chicago, IL, USA).
Results
Ficolin-3 levels in stimulated platelet-derived microvesicles
In order to see whether ficolin-3 could be released by platelet-derived microvesicles, we stimulated platelets with ADP and collected the conditioned medium after 2 h. Ficolin-3 levels were significantly higher in both conditioned medium and microvesicles (exosomes and MPs) isolated from conditioned medium of ADP-stimulated platelets (P < 0.05, Fig. 1A) . Moreover, the analysis by NTA showed an increase in the number of particles in ADP-stimulated platelets (Table S1 ). Moreover, we confirmed by flow cytometry the presence of microvesicles positive for the platelet marker CD41 and Anexin V ( Figure S1 ).
Ficolin-3 levels in AAA tissue and tissue-conditioned medium
In this study, we analyzed ficolin-3 levels in microvesicles isolated from tissue-conditioned medium from AAAs (thrombus and wall) and healthy aortic wall. Ficolin-3 levels were significantly higher in microvesicles from conditioned media of AAA thrombus and wall compared with healthy wall (P < 0.05, Fig. 1B) . Moreover, the analysis by NTA showed an increase in the number of particles released by pathological tissue (wall and thrombus) compared with healthy wall (Table S1 ). We also analyzed by flow cytometry the cell origin of microvesicles present in AAA tissue-conditioned medium. Increased staining was observed for CD41 and CD14 in microvesicles obtained from both thrombi and wall compared with healthy wall (Fig. 2A) . Moreover, CD15 staining was increased in AAA thrombus microvesicles compared with those from healthy wall. Additionally, we analyzed FCN3 mRNA levels in human AAA wall compared with healthy wall. Interestingly, FCN3 mRNA levels in the AAA wall were greatly increased compared with healthy walls (P < 0.05, Fig. 2B ). No detectable FCN3 mRNA was obtained from the majority of thrombi analyzed (not shown), as previously observed for complement C3 [18] . Finally, we analyzed ficolin-3 immunostaining in human AAA thrombus and wall, as well as in healthy wall. As can be observed in Fig. 2(C) , ficolin-3 was present in both AAA thrombus and wall, whereas only faint staining was present in healthy wall.
Ficolin-3 concentration in plasma of AAA patients
In order to address the potential role of ficolin-3 as a biomarker of AAA, we analyzed ficolin-3 levels in plasma of AAA patients (n = 478) and controls (n = 176). Clinical characteristics are shown in Table 1 Fig. 3A) . Logistic regression analysis showed that the significant association between increased ficolin-3 levels and presence of AAA persisted after adjustment for risk factors (adjusted OR, 5.29; 95% confidence interval [CI], 3.27, 8.57) ( Table 2) . ROC curve analyses showed that ficolin-3 levels were significantly better predictors of AAA presence (AUC [95% CI], 0.7 [0.69-0.77]; P < 0.001; Fig. 3B ] than CRP levels (AUC, 0.650; difference in area, 0.076; standard error of the difference, 0.0308; Z, 2.2653; P = 0.014). Moreover, we also analyzed the potential association of ficolin-3 with aortic diameter, a surrogate marker of AAA evolution. A positive association of these two parameters was observed (Spearman 0 s rho, 0.25; P < 0.001), after adjustment for potential confounding factors (Table 3) . Similarly, CRP correlated with aortic diameter, as previously reported [15] . Cox regression analyses of the association of ficolin-3 levels above and below the median and the need for later preventive repair showed a significant increased risk if the ficolin-3 level was above the median, which was after adjustment for potential confounding factors (adjusted hazard ratio, 1.55; 95% CI, 1.11, 2.15)] (Table 4 ). In contrast, CRP was not associated with the need for later preventive repair. The survival curves of the association with need for surgical repair for both ficolin-3 and CRP concentrations above and below the median are shown in Fig. 4 , and suggest that ficolin-3 is associated with AAA evolution.
Discussion
The identification of novel biomarkers of AAA may facilitate diagnosis of AAA and prediction of its evolution, as well as defining possible targets for new medical treatments to slow AAA progression. Microvesicles are an interesting source of circulating biomarkers because they can transport important information (e.g. miRNA and proteins) potentially derived from both activated circulating cells and tissue [22] . In the present study, we addressed the potential extra-hepatic origin of the increased ficolin-3 previously found in microvesicles isolated from plasma of AAA patients by proteomic analysis [7] . Platelets are generally considered as the principal cells involved in the release of blood-borne microvesicles. Moreover, we have recently observed that ficolin-3 is present in platelets [23] . We have shown that ficolin-3 levels were increased in platelets from healthy subjects incubated with ADP, which was associated with microvesicles. Moreover, we also observed increased ficolin-3 levels in microvesicles isolated from AAA thrombus-conditioned and wall-conditioned media. The number of particles was higher in activated platelets and pathological tissue (wall and thrombus) compared with healthy wall. In contrast, protein concentration was similar in all groups, suggesting that the increased ficolin-3 expression observed in microvesicles of activated platelets and pathological tissue was a result of an increased proportion of particles enriched in ficolin-3 protein.
In addition, to characterize the cell origin of these tissue microvesicles, we used flow cytometry to analyze the staining for markers of leukocytes (monocytes and neutrophils), RBCs, endothelial cells and vascular smooth muscle cells. Interestingly, we observed that staining for platelets, and also leukocytes, was increased in microvesicles obtained from thrombus and wall, compared with those from healthy wall. In this respect, the contribution of neutrophils to the release of microvesicles by both the thrombus and the wall has been recently demonstrated [24] . Interestingly, ficolin-3 mRNA expression was markedly increased in the AAA wall compared with healthy wall, suggesting an active process of synthesis and secretion by cells present in the AAA wall. Thus, the extrahepatic origin of high ficolin-3 levels in microvesicles from plasma of AAA patients could be, at least in part, the activated cells present both in the circulation and in the pathological tissue.
Complement proteins have been previously detected in human AAA tissue [25] [26] [27] . We have shown increased immunostaining of ficolin-3 in both AAA thrombus and wall. On the one hand, AAA thrombus can be envisioned as a privileged location for crosstalk between the coagulation and complement systems because it is highly enriched in many cells and molecules that favour the interaction between these two systems (leukocytes, platelets, proteases and complement components) [18, 28, 29] . The interaction between coagulation and complement systems is reciprocal [30, 31] . In addition to the three well-known pathways of complement activation (the classical, the lectin and the alternative pathway), the extrinsic pathway involves proteolytic degradation of C3 by proteases such as elastase, plasmin or thrombin [32] . Moreover, complement activation in the fluid phase can be triggered by molecules released from thrombin-activated platelets (e.g. chondroitin sulfate) [33] . Complement proteins, inhibitors and regulators have been identified in platelets and platelet-derived microvesicles [34] . Moreover, it has been recently reported that activated platelets bind ficolin-1, -2 and -3 and activate MASP-1 and -2 during blood clotting [23] . On the other hand, AAA is characterized by a chronic immune-inflammatory response in the wall [35] [36] [37] . The adventitial inflammatory infiltrate in AAA is dominated by T and B cells, along with plasma cells and IgGs, which are organized in lymphoid tertiary organs [38] . Interestingly, an interaction between ficolin-3 and natural IgG antibodies has been demonstrated [39] . In this regard, mice deficient in B cells (and hence antibodies) are protected against aneurysm formation [40] . Moreover, a natural IgG that binds to fibrinogen deposited in elastaseperfused aortic tissues, activates the lectin pathway of the complement system and induces AAA [14] . Therefore, high levels of ficolin-3 in the AAA thrombus could be involved in complement-coagulation crosstalk in human AAAs, whereas ficolin-3 in the AAA wall could be involved in the immune-inflammatory response associated with AAA. Most AAAs are asymptomatic and they are often detected as an incidental finding during the investigation of an unrelated problem or as a consequence of radiological screening. Moreover, AAA evolution is unpredictable and so, in patients with diagnosed AAA, tools in addition to serial imaging by ultrasound would greatly help in individual patient management. Thus, besides elucidating the local role of ficolin-3 in AAA tissue, we were interested in the potential role of ficolin-3 as a biomarker of AAA. The normal range of ficolin-3 has been found to be 3.5-54 micrograms/ml in blood donors, with a mean concentration of 26 micrograms/ml [17] . Increased ficolin-3 levels have been observed in systemic lupus erythematosus patients compared with healthy subjects [41, 42] and high levels of ficolin-3 have been associated with decreased kidney graft survival [43, 44] . We observed an increase in ficolin-3 levels in a large cohort of AAA patients compared with controls, which persisted after adjustment for risk factors. However, it is generally assumed that any individual biomarker alone would be insufficient for prediction of such a complex disease as AAA. The use of a combination of biomarkers has been shown to predict patients who are at higher risk of AAA [45] . Regarding surrogate markers of AAA growth, the aortic diameter is still the most widely used marker of AAA evolution [46] . We observed a positive association of ficolin-3 with aortic diameter, which was after adjustment for potential confounding factors. Moreover, we also observed a strong positive correlation of ficolin-3 with the need for surgical repair, independently of aortic diameter, among other factors. Of particular interest was the comparison with CRP, showing that ficolin-3 was superior in terms of sensitivity in detecting AAA; moreover, CRP levels did not correlate with time to surgery as did ficolin-3. Although we made considerable efforts to adjust for confounders, this study, like all observational studies, carries the risk of residual confounding. Nevertheless, on the whole, our data suggest that ficolin-3 is associated with the presence and evolution of AAA.
The present study has some limitations. Firstly, we used EDTA plasma to isolate microvesicles, although there are contradictory published reports as to the preferred plasma sampling method to isolate microparticles (i.e. use of the anticoagulants citrate, EDTA or heparin) [47] [48] [49] [50] . Secondly, the ficolin-3 hypothesis was formulated after plasma sampling and no previous data existed regarding ficolin-3 in AAA to enable prior calculation of sample size. Consequently, the number of controls depended only on the samples available at the beginning of the Viborg vascular study, with the consequence that the analytical power may have been inadequate. However, in a post-hoc power calculation using the number of available AAAs and control samples, the lowest detectable difference at the 5% significance level and 80% power was 10.6 mmol L
À1
. As we observed a 24.4 mmol L À1 difference, this indicates a rather robust finding.
In conclusion, we have shown that ficolin-3 can be released either by activated cells or pathological AAA tissue via microvesicles into the extracellular medium. Ficolin-3 plasma levels are associated with the presence and progression of AAA, suggesting its potential role as a biomarker of AAA. 
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